In last trading session, Cytokinetics Inc (NASDAQ:CYTK) saw 1.19 million shares changing hands with its beta currently measuring 0.84. Company’s recent per share price level of $38.00 trading at $0.19 or 0.50% at ring of the bell on the day assigns it a market valuation of $4.53B. That closing price of CYTK’s stock is at a discount of -80.95% from its 52-week high price of $68.76 and is indicating a premium of 13.84% from its 52-week low price of $32.74. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.44 million shares which gives us an average trading volume of 1.99 million if we extend that period to 3-months.
For Cytokinetics Inc (CYTK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.32. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Upright in the green during last session for gaining 0.50%, in the last five days CYTK remained trading in the red while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $38.00 price level, adding 4.35% to its value on the day. Cytokinetics Inc’s shares saw a change of -19.22% in year-to-date performance and have moved -1.45% in past 5-day. Cytokinetics Inc (NASDAQ:CYTK) showed a performance of -18.40% in past 30-days. Number of shares sold short was 14.33 million shares which calculate 8.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 67 to the stock, which implies a rise of 43.28% to its current value. Analysts have been projecting 67 as a low price target for the stock while placing it at a high target of 67. It follows that stock’s current price would drop -76.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of -76.32% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.02% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -8.39% while estimates for its earnings growth in next 5 years are of 18.86%.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
Insiders are in possession of 0.72% of company’s total shares while institution are holding 114.65 percent of that, with stock having share float percentage of 115.48%. Investors also watch the number of corporate investors in a company very closely, which is 114.65% institutions for Cytokinetics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CYTK for having 14.67 million shares of worth $794.97 million. And as of 2024-06-30, it was holding 13.4317 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 11.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.5485 of outstanding shares, having a total worth of $624.32 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Core S&P Mid-Cap ETF are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 4.07 shares of worth $154.58 million or 3.41% of the total outstanding shares. The later fund manager was in possession of 3.85 shares on Mar 31, 2025 , making its stake of worth around $146.49 million in the company or a holder of 3.23% of company’s stock.
